Key Highlights

● Precigen, Inc. (PGEN) shares fell 9.37% to close at $7.74 on Monday, October 5, 2026.

● No confirmed company-specific release was identified for the session.

● The drop is most accurately framed as part of a broader biotech selloff rather than a reaction to any company announcement.

● The decline came even as the broad market advanced, led by technology and growth.

Precigen, Inc. (NASDAQ:PGEN) ranked among the weaker performers in the US session on Monday, October 5, 2026, closing at $7.74, a daily loss of 9.37%. The decline came even as the broad market advanced, with the S&P 500 up 0.66%, the Nasdaq Composite up 1.05% and the small-cap Russell 2000 up 0.72%. No confirmed company-specific release was identified for the session.

A Sector Pullback, Not a Company Event

Biotechnology shares, particularly clinical-stage and smaller-capitalization names, are known for pronounced volatility. Their valuations often hinge on expectations about future data and programs rather than current cash flows, which makes them sensitive to swings in risk appetite, rotation among sectors, and profit-taking after prior gains. PGEN's decline is consistent with that kind of sector-wide dynamic.

A Rate Backdrop Weighing on Long-Duration Names

The session was also marked by an unusual divergence, as Treasury yields surged despite a soft September jobs report, with the 10-year yield reaching a fresh roughly 52-week high near 5.31%. Rising yields can weigh on the valuations of long-duration, earnings-distant companies, a category into which many development-stage biotechs fall, though this general backdrop is context rather than a confirmed cause of PGEN's decline specifically.

Sector Pressure, Not a Company Verdict

The confirmed facts are limited: the closing price, the size of the daily decline, and the absence of any company-specific release to explain it, within a broader biotech pullback. On a session when optimism around a potentially easier rate path lifted much of the market, PGEN moved the other way.